In vitro inhibition of testicular Δ5-3β-hydroxysteroid dehydrogenase and prostatic 5α-reductase activities in rats and humans by Strogen forte extract

International Urology and Nephrology

Volumn 28, Issue 3, 1996, Pages 337-348

  Toth I ^a   Szecsi M ^a   Julesz, J ^a   Faredin, I ^a   Behnke, B ^b  

^a UNIVERSITY OF SZEGED   (Hungary)

^b Pharma Stroschein GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; PLANT EXTRACT; STEROID 5ALPHA REDUCTASE;

ARTICLE; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; MALE; NONHUMAN; PROSTATE; RAT; TESTIS;

EID: 0029815528     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02550496     Document Type: Article

References (29)

1. Blohm, T. R., Laughlin, M. E., Benson, H. D., Johnston, J. O., Wright, C. L., Shaternan, G. L., Weintraub, C. M.: Pharmacological induction of 5α-reductase deficiency in the rat: Separation of testosterone-mediated and 5αdihydrotestosterone-mediated effects. Endocrinology, 119, 959 (1986).
2. Breier, M.: Effect of Strogen forte treatment in stages II and III of BPH (in Hungarian), Pharma Stroschein GmbH: Strogen forte Symposium, May 1944, Budapest.
3. Cabin, B. E., Larson, B., Lindahl, O.: Treatment of benign prostatic hyperplasia with phytosterols. Br. J. Urol., 66, 639 (1990).
4. Carilla, E., Briley, M., Fauran, F., Sultan, Ch., Duvilliers, C.: Binding of Permixon, a new treatment for prostatic benign hyperplasia, to the cystosolic androgen receptor in the rat prostate. J. Steroid. Biochem., 20, 521 (1984).
5. Champault, G., Petel, J. C., Bennard, A. M.: A double blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. Br. J. Clin. Pharmacol., 18, 461 (1984).
6. Düker, E. M., Kopanski, L., Schweikert, H.-U.: Inhibition of Soc-reductase activity by extracts from Sabal serrulata, Phanta Med., 55, 587 (1989).
7. Faredin, T., Tóth, I., Oszlánczy, J., Scultéty, S.: Activity and inhibition of human prostatic 5α-reductase (in Hungarian). Magy. Urol., 3, 289 (1991).
8. Faredin, I., Toth, I., Oszlánczy, J., Scultéty, S.: In vitro study of rat prostate 5α-reductase activity and its inhibition. Int. Urol. Nephrol., 24, 145 (1992).
9. George, F. W., Peterson, K. G.: 5α-dihydrotestosterone formation is necessary for embryogenesis of the rat prostate. Endocrinology, 122, 1159 (1988).
10. Hagenlocher, M., Romalo, G., Schweikert, H. U.: Spezifische Hemmung der 5α-Reductase durch einen neuen Extrakt aus Sabal serrulata. Aktuel. Urol., 24, 146 (1993).
11. Kondás, J.: Changes of urodynamic and clinical parameters of BPH after 6 month Strogen forte treatment (in Hungarian). Pharma Stroschein GmbH: Strogen forte Symposium, May 1994, Budapest.
12. Lowry, O. H., Rosenbrough, N. J., Farr, A. L., Randall, R. J.: Protein measurement with the Folin Phenol reagent. J. Biol. Chem., 193, 265 (1951).
13. Julesz, M., Faredin, I., Tóth, I.: Steroids in human skin. Akadémiai Kiadó, Budapest 1971, p. 155.
14. Metcalf, B. W., Levy, M. A., Hold, D. A.: Inhibitors of steroid 5α-reductase in benign prostatic hyperplasia, male pattern baldness and acne. TiPS, 10, 491 (1989).
15. Mühlbauer, S.: Sabal serrulata in der BPH-Therapie: Portrait eines Phytopharmakons. Fortschr. Med., 109 (Monographia 51), 3-4 (1991).
16. Rhodes, L., Primke, R. L., Berman, Ch., Vergutt, G., Gabriel, M., Pierre-Malloe, M., Gibelin, B.: Comparison of finasteride (Proscar) as 5α-reductase inhibitor and various commercial plant extracts in in vitro and in vivo 5α-reductase inhibition. The Prostate, 22, 43-51 (1993).
17. Romics, J., Schmitz, H., Frang, D.: Experience in treating benign prostatic hypertrophy with Sabal serrulata for one year (in Hungarian). Magy. Urol., 5, 343 (1993).
18. Romics, J., Schmitz, H., Frang, D.: Experience in treating benign prostatic hypertrophy with Sabal serrulata for one year. Int. Urol. Nephrol., 25, 565 (1993).
19. Sansone, G., Reisner, R. M.: Differential rates of conversion of testosterone to dihydrotestosterone in acne and normal skin - a possible pathogenic factor in acne. J. Invest. Dermatol., 56, 366 (1971).
20. Schultz, F. M., Wilson, J. D.: Virilization of the Wolffian duct in the rat fetus by various androgens. Endocrinology, 94, 979 (1974).
21. Scultéty, S., Oszlánczy, J., Faredin, L., Tóth, I.: High-dose ketoconazole treatment in advanced prostatic cancer. Int. Urol. Nephrol., 20, 383 (1988).
22. Szécsi, M., Tóth, I., Rengei, B., Scultéty, S., Faredin, I.: Androgenic steroids in normal and hyperplastic prostatic tissue samples. In: S. Göróg (ed.): Advances in Steroid Analysis '93. Akadémiai Kiadó, Budapest 1994, pp. 485-488.
23. Szécsi, M., Tóth, I., Julesz, J., Faredin, I., Behnke, B.: Effect of "Strogen forte" extract on the testicular Δ5-3β-hydroxysteroid dehydrogenase activity in vitro (Abstract). Eur. J. Endocrinol., 130, 120 (1994).
24. Szécsi, M., Tóth, I., Faredin, I.: The levels of androgens in rat prostate and serum after castration. Endocrine Regulation, 29, 107 (1995).
25. Tóth, I., Faredin, T., Scultéty, S.: Kinetic analysis of rat testicular Δ-3β-hydroxysteroid dehydrogenase inhibition by cyproterone acetate in vitro (in Hungarian). Magy. Urol., 3, 299 (1991)
26. Tóth, I., Tuba, Z., Horváth, J., Scultéty, S., Szécsi, M., Faredin, I.: Inhibition of human testicular and dermal Δ-3β-hydroxysteroid dehydrogenase activity in vitro. In: S. Görög (ed.): Advances in Steroid Analysis '93. Akadémiai Kiadó, Budapest 1994, pp. 391-396.
27. Tóth, I., Szécsi, M., Julesz, J., Faredin, I., Behnke, B.: Effect of "Strogen forte" extract on the prostatic 5α-reductase activity in vitro (Abstract). Eur. J. Endocrinol., 130, 53 (1994).
28. Tóth, I., Faredin, I.: Measurements and inhibition of dermal Δ-3β-hydroxysteroid dehydrogenase activity in vitro (in Hungarian). Klin. Kisérl. Lab. Med., 22, 235 (1995).
29. Webster, M. A., Gillmer, M. D. G.: Induction of abortion in early first trimester human pregnancy using epostane. Br. J. Obstet. Gynaecol., 96, 340 (1989).